Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Figures

• 

  Fig. 1. Target lesion changes in patients with soft tissue sarcoma treated with nanoparticle albumin-bound paclitaxel plus a programmed cell death protein 1 inhibitor. A Waterfall plot shows the maximum reduction of target lesion size from baseline evaluated according to the Response Evaluation Criteria for Solid Tumors (RECIST, version 1.1). The horizontal axis represents different patients, and the vertical axis represents the percentage of change in the target lesions. One patient with angiosarcoma had a complete response (100% decrease in target lesion size), six patients had a partial response (30% and more decrease in target lesion size), seven patients had stable disease (< 20% increase and < 30% decrease in target lesion size), and 14 patients had progressive disease (20% and more increase in target lesion size). B Line plot shows the duration of response of the target lesions from baseline evaluated according to RECIST (version 1.1). Each line represents the change in the size of a patient’s target lesion over the time of treatment. Patients with a complete or partial response are indicated in green, those with progressive disease in red, and those with stable disease in yellow

• 

  Fig. 2. Univariate Cox regression analysis of the relationship between clinicopathological parameters and progression-free survival (PFS). When the hazard ratio (HR) (95% CI) of a factor is completely on the right side of the dotted line, it means that it is a risk factor; When it is completely to the left of the dotted line, it means that it is a protective factor; When the dotted line is included, it cannot be judged whether it is a risk factor or a protective factor. Among the patients in this study, those with angiosarcoma had a significantly longer PFS compared to those with other pathological subtypes (HR = 0.20, 95%CI 0.06 - 0.70, P = 0.012); those with the primary tumor site in the head region had a significantly longer PFS than those with the primary tumor at other sites (HR = 0.20, 95%CI 0.04 - 0.99, P = 0.048); those who experienced three or more adverse events (AEs) had significantly longer PFS than those who experienced less than three AEs (HR = 0.36, 95%CI 0.16 - 0.84, P = 0.018). ECOG PS, eastern cooperative oncology group performance status; mPFS, median PFS